運動 症状 に 与える 影響 に 加え て,子宮頸 部 ディストニア に 関する ボトリウム 毒 の 治療 の"非 運動 効果"は あり ます か
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。ボトリヌム毒素A (BoNT) は,頸部ジストニアの運動症状を効果的に治療する. この研究では BoNTはCD患者のうつ病や認知機能などの 非運動症状を有意に改善することが示されています
科学分野
- 神経学
- 薬理学について
背景
- 子宮頸部ジストニア (CD) は,主にボツリヌム毒素A (BoNT) で運動症状を治療します.
- 新興の証拠によると,BoNTはCD患者の非運動症状 (NMS) にも影響を与える可能性がある.
研究 の 目的
- 子宮頸部ジストニアの成人の患者の運動および非運動症状に対するBoNTの影響を包括的に評価する.
- 治療後の結果と対照群を比較する
主な方法
- 34人の成人CD患者は,BoNT治療前のおよび後の臨床的および機能的評価を受けた.
- 運動症状 (静脈痛の重度,歩行) と非運動症状 (認知,うつ,不安,睡眠,痛み) を評価した.
- 結果は対照群と比較した.
主要な成果
- BoNT治療は,以前の研究と一致して,運動症状の有意な改善をもたらしました.
- 非運動症状に対するBoNTの顕著な効果が観察されました.
- うつ病と認知機能の改善は NMSの中で最も顕著でした.
結論
- ボトリヌム毒素Aは,子宮頸部ジストニアの患者の非運動症状の改善に潜在性を示しています.
- 様々な非運動症状に対するBoNTの有効性は均一ではありません.
- CDにおけるBoNTの包括的な効果を完全に解明するには,さらなる研究が必要である.
関連する概念動画
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...